In this study, the anti-inflammatory drug (canakinumab) in 150-mg and 300 mg doses, four times a year, achieved a 40% relative risk reduction (RRR) in plasma CRP and IL-6 levels, in addition to a 15% RRR in the incidence of MI, stroke, or CV death. Here, IL6 is linked to stroke disorder.